Why Is Novo Stock (NVO) Falling in Pre-Market Today, September 21?
Novo Nordisk (NVO) stock fell 5% pre-market after setting a 2035 sales target of $23B, which failed to reassure investors. Morgan Stanley (MS) predicts Novo will lose market share to Lilly (LLY) in obesity and diabetes. Novo's Q2 2026 sales rose 7% YoY to $12.1B, but it expects a 6% YoY decline in 2026 adjusted sales and operating profit, better than earlier forecasts. The company plans to launch five 'multi-blockbusters' by 2030.
How this was made
The 30-second read
Why it matters
The announcement highlights competitive pressure from Eli Lilly and may lead to re‑rating of growth expectations.
Market read
Novo's guidance shortfall drives immediate price decline and could influence sector sentiment.
What to watch
Recent Phase 3 trial successes and upcoming oral GLP‑1 launch could offset short‑term concerns.
Background
Novo Nordisk disclosed a new long‑term sales target at its Capital Markets Day, prompting a pre‑market sell‑off.
Ticker impact
Shares fell >5% in pre‑market after CEO announced a 2035 sales target of >DKK 150 bn, which failed to reassure investors.
Further downside pressure in early trading.
Guidance short of market expectations and competitive pressure from Eli Lilly triggered a sharp sell‑off.
Market effects
Obesity/diabetes drug sector may see heightened scrutiny of growth forecasts.
European pharma stocks could face similar pressure if guidance falls short.
Potential ripple to peers like Eli Lilly (LLY) as investors compare growth outlooks.
Counterpoint
The long‑term 2035 target may signal confidence in pipeline, offering a buying opportunity on dip.
Key entities
- companyNovo Nordisk A/S
Danish pharmaceutical company, ticker NVO.
- companyEli Lilly and Co.
U.S. competitor in obesity/diabetes market, ticker LLY.
